The Drug “Humulin”
American pharmaceutical company “R-Pharm signed at SPIEF-2016 contract manufacturing of drugs “Humulin”, “Humalog” and the analogue of long-acting insulin at the facilities of the Russian manufacturer.
The previous contract signed by the companies in 2014, suggested that in Russia there is only the packaging of insulin human. Under the new agreement, “Lilly” will import the original substance (crystals), and dosage form of drugs will be done “R-Pharm”, said Lilli. In addition to human insulin will be produced and analog.
“The result of the agreement will be not only receiving technology from the company “Lilly” […], now, thanks to the localization of production of innovative products, we can guarantee uninterrupted supply of the treatment process all patients through its own resources, its own capacities. In addition, the contract will allow the company “R-Pharm to expand the scope of manufactured products” — quoted in the joint press release of companies General Director of “R-Pharm Vasily Ignatiev.
According to General Director of “Lilly” in Russia, Ukraine, CIS countries and Israel, Eric Patriarca, the agreement with the Russian partner was a response to the growing epidemic of diabetes and the high demand for insulin in the country.
At the end of 2015 in an interview with RBC head of rostec Sergei Chemezov said that Russia’s full-cycle production of insulin is only the company “GEROPHARM”.
Total investments of “R-Pharm” and “Lilly” in manufacturing will be about $100 million of the Company also discussed the possibility of extension, localization and other drugs.